Acute Pharmacodynamic Effects of Empagliflozin With and Without Diuretic Agents in Patients With Type 2 Diabetes Mellitus

Clinical Therapeutics

Volumn 38, Issue 10, 2016, Pages 2248-2264.e5

  Heise, Tim ^a   Jordan, Jens ^b   Wanner, Christoph ^c   Heer, Martina ^a   Macha, Sreeraj ^d   Mattheus, Michaela ^e   Lund, Søren S ^e   Woerle, Hans J ^e   Broedl, Uli C ^e  

^a Profil   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d MERCK RESEARCH LABORATORIES   (United States)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

diuresis; hydrochlorothiazide; pharmacodynamics; torasemide

Indexed keywords

ALDOSTERONE; EMPAGLIFLOZIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HYDROCHLOROTHIAZIDE; RENIN; SODIUM; TORASEMIDE; URIC ACID; BENZHYDRYL DERIVATIVE; DIURETIC AGENT; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2; SULFONAMIDE;

ADULT; AGED; ALDOSTERONE BLOOD LEVEL; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLUID INTAKE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE URINE LEVEL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PHARMACODYNAMICS; PLASMA RENIN ACTIVITY; POLYDIPSIA; RANDOMIZED CONTROLLED TRIAL; SERUM OSMOLALITY; SODIUM INTAKE; SODIUM METABOLISM; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; URIC ACID URINE LEVEL; URINE OSMOLALITY; URINE VOLUME; ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; MIDDLE AGED;

ADULT; AGED; BENZHYDRYL COMPOUNDS; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIURETICS; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSIDES; HUMANS; HYDROCHLOROTHIAZIDE; MALE; MIDDLE AGED; SODIUM-GLUCOSE TRANSPORTER 2; SULFONAMIDES;

EID: 84994351221     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2016.08.008     Document Type: Article

References (37)

1. 1 Grempler, R., Thomas, L., Eckhardt, M., et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 14 (2012), 83–90.
2. 2 Häring, H.U., Merker, L., Seewaldt-Becker, E., et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Care 37 (2014), 1650–1659.
3. 3 Häring, H.U., Merker, L., Seewaldt-Becker, E., et al. Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled trial. Diabetes Care 36 (2013), 3396–3404.
4. 4 Kovacs, C.S., Seshiah, V., Swallow, R., et al. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial. Diabetes Obes Metab 16 (2013), 147–158.
5. 5 Roden, M., Weng, J., Eilbracht, J., et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 1 (2013), 208–219.
6. 6 Sarafidis, P.A., Georgianos, P.I., Lasaridis, A.N., Diuretics in clinical practice. Part I: mechanisms of action, pharmacological effects and clinical indications of diuretic compounds. Expert Opin Drug Saf 9 (2010), 243–257.
7. 7 Muller, M.J., Bosy-Westphal, A., Klaus, S., et al. World Health Organization equations have shortcomings for predicting resting energy expenditure in persons from a modern, affluent population: generation of a new reference standard from a retrospective analysis of a German database of resting energy expenditure. Am J Clin Nutr 80 (2004), 1379–1390.
8. 8 Heise, T., Mattheus, M., Woerle, H.J., et al. Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study. Clin Ther 37 (2015), 793–803.
9. 9 Barzilay, J.I., Davis, B.R., Cutler, J.A., et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 166 (2006), 2191–2201.
10. 10 Gress, T.W., Nieto, F.J., Shahar, E., et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 342 (2000), 905–912.
11. 11 Mukete, B.N., Rosendorff, C., Effects of low-dose thiazide diuretics on fasting plasma glucose and serum potassium—a meta-analysis. J Am Soc Hypertens 7 (2013), 454–466.
12. 12 Houston, M.C., The effects of antihypertensive drugs on glucose intolerance in hypertensive nondiabetics and diabetics. Am Heart J 115 (1988), 640–656.
13. 13 Ellison, D.H., Diuretic resistance: physiology and therapeutics. Semin Nephrol 19 (1999), 581–597.
14. 14 Knauf, H., Mutschler, E., Clinical pharmacokinetics and pharmacodynamics of torasemide. Clin Pharmacokinet 34 (1998), 1–24.
15. 15 Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Inter Suppl 3 (2013), 1–150.
16. 16 Ponikowski, P., Voors, A.A., Anker, S.D., et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 37 (2016), 2129–2200.
17. 17 Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
18. 18 Wanner, C., Inzucchi, S.E., Lachin, J.M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med 375 (2016), 323–334.
19. 19 Vallon, V., Gerasimova, M., Rose, M.A., et al. SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol 306 (2014), F194–F204.
20. 20 Cherney, D.Z., Perkins, B.A., Soleymanlou, N., et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 129 (2014), 587–597.
21. 21 Hansen, H.P., Rossing, P., Tarnow, L., et al. Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy. Kidney Int 47 (1995), 1726–1731.
22. 22 Apperloo, A.J., de Zeeuw, D., de Jong, P.E., A short-term antihypertensive treatment-induced fall in glomerular filtration rate predicts long-term stability of renal function. Kidney Int 51 (1997), 793–797.
23. 23 Ortola, F.V., Ballermann, B.J., Anderson, S., et al. Elevated plasma atrial natriuretic peptide levels in diabetic rats. Potential mediator of hyperfiltration. J Clin Invest 80 (1987), 670–674.
24. 24 Ridderstrale, M., Andersen, K.R., Zeller, C., et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol 2 (2014), 691–700.
25. 25 Baker, W.L., Smyth, L.R., Riche, D.M., et al. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens 8 (2014), 262–275.
26. 26 Cherney, D.Z., Perkins, B.A., Soleymanlou, N., et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol, 13, 2014, 28.
27. 27 Dunn, C.J., Fitton, A., Brogden, R.N., Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs 49 (1995), 121–142.
28. 28 Wilcox, C.S., Mitch, W.E., Kelly, R.A., et al. Factors affecting potassium balance during frusemide administration. Clin Sci (Lond) 67 (1984), 195–203.
29. 29 Palmer, B.F., Metabolic complications associated with use of diuretics. Semin Nephrol 31 (2011), 542–552.
30. 30 Lytvyn, Y., Škrtić, M., Yang, G.K., et al. Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus. Am J Physiol Renal Physiol 308 (2015), F77–83.
31. 31 Chino, Y., Samukawa, Y., Sakai, S., et al. SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. Biopharm. Drug Dispos 35 (2014), 391–404.
32. 32 Sica, D.A., Carter, B., Cushman, W., et al. Thiazide and loop diuretics. J Clin Hypertens 13 (2011), 639–643.
33. 33 Goicoechea, M., de Vinuesa, S.G., Verdalles, U., et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5 (2010), 1388–1393.
34. 34 Goicoechea, M., Garcia de Vinuesa, S., Verdalles, U., et al. Allopurinol and progression of CKD and cardiovascular events: long-term follow-up of a randomized clinical trial. Am J Kidney Dis 65 (2015), 543–549.
35. 35 Kleber, M.E., Delgado, G., Grammer, T.B., et al. Uric acid and cardiovascular events: a mendelian randomization study. J Am Soc Nephrol 26 (2015), 2831–2838.
36. 36 Palmer, T.M., Nordestgaard, B.G., Benn, M., et al. Association of plasma uric acid with ischaemic heart disease and blood pressure: mendelian randomisation analysis of two large cohorts. BMJ, 347, 2013, f4262.
37. 37 Ferrannini, G., Hach, T., Crowe, S., et al. Energy balance following sodium-glucose co-transporter-2 inhibition. Diabetes Care 38 (2015), 1730–1735.